Aclaris Therapeutics (ACRS) Cost of Revenue (2017 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Cost of Revenue came in at $395000.0 in Q1 2026, down 21.94% year-on-year from $506000.0 in Q1 2025, and down 25.75% quarter-over-quarter from $532000.0 in Q4 2025.
Aclaris Therapeutics (ACRS) Cost of Revenue (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $395000.0 for Q1 2026.
- On a quarterly basis, Cost of Revenue fell 21.94% year-over-year to $395000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 20.45% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 25.11% from the prior year.
- Cost of Revenue eased to $395000.0 in Q1 2026 per ACRS's latest filing, from $532000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.2 million in Q1 2022 and bottomed at $395000.0 in Q1 2026.
- The 5-year median for Cost of Revenue is $725000.0 (2023), against an average of $748470.6.
- Biggest YoY gain for Cost of Revenue was 0.12% in 2024; the steepest drop was 40.12% in 2024.
- Year by year, Cost of Revenue stood at $877000.0 in 2022, then retreated by 17.33% to $725000.0 in 2023, then retreated by 2.76% to $705000.0 in 2024, then dropped by 24.54% to $532000.0 in 2025, then decreased by 25.75% to $395000.0 in 2026.
- Per Business Quant, the three latest ACRS Cost of Revenue figures stand at $395000.0 (Q1 2026), $532000.0 (Q4 2025), and $538000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Aclaris Therapeutics | 687.20 Mn | 581.79 Mn | 1.60 Mn | 395,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 395,000.00 |
| Mar 31, 2026 | 395,000.00 |
| Dec 31, 2025 | 532,000.00 |
| Dec 31, 2025 | 532,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 506,000.00 |
| Mar 31, 2025 | 506,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Sep 30, 2024 | 654,000.00 |
| Sep 30, 2024 | 654,000.00 |
| Jun 30, 2024 | 624,000.00 |
| Jun 30, 2024 | 624,000.00 |
| Mar 31, 2024 | 809,000.00 |
| Mar 31, 2024 | 809,000.00 |
| Dec 31, 2023 | 725,000.00 |
| Dec 31, 2023 | 725,000.00 |